Eli Lilly’s partnership with Amazon to boost presence in diabetes and obesity markets (with abstract)
Article published by [[Other sources |Pharmaceutical technology]] and reviewed by Nikolay Sidelnikov
| Eli Lilly’s partnership with Amazon to boost presence in diabetes and obesity markets (with abstract) | |
|---|---|
| Published By | [[Pharmaceutical technology]] |
| Publish Date | March, 2024 |
| Authors | GlobalData Healthcare |
| Topics | B2B eCommerce in Pharma, D2C |
| Statistics | |
| Article Size | words |
| Diagrams | No |
| Downloadable Version | No |
| Reviewers | |
| Page Owner | Nikolay Sidelnikov |
| Summary Author | Nikolay Sidelnikov |
Abstract
The short article Eli Lilly’s partnership with Amazon to boost presence in diabetes and obesity markets was published by Pharmaceutical Technology in 2024 and discloses some aspects of D2C strategy of Eli Lilly, the biggest pharma company by market value.
- In January 2024, the company launched LillyDirect, its direct-to-consumer distribution network.
- Eli Lilly started partnering with online pharmacies such as Truepill.
- Im March of 2024 Eli Lilly and Amazon decided to partner up. LillyDirect allows for online consultations and prescriptions, and Amazon delivers medicines to the patient’s home, offering fast delivery and discounts.
Also some insights on competition of Eli Lilly and Novo Nordisk a mentioned.
Quote
Now, Eli Lilly has also started to boost its distribution channels. It will be interesting to see whether Novo Nordisk will make a similar move in the next few months.